Cosmo Pharmaceuticals S.p.A. CEO Sees $1.5 Billion Dye Luring Buyer by 2013

Published: Sep 25, 2012

Cosmo Pharmaceuticals SpA (COPN), the developer of a dye that may help detect pre-cancerous colon growths, plans to use the product to lure a buyer within the next year, Chief Executive Officer Mauro Ajani said. More than 10 companies have expressed interest in the dye, called Methylene Blue MMx, and the company expects to start talks before April, Ajani said in an interview at Cosmo’s headquarters in Lainate, near Milan. The company probably won’t sell rights to the product separately because it would reduce the appeal of the company to a potential acquirer, Ajani said.

Back to news